Table 6 Results of outcome measures to evaluate physical functioning after MIS THA*
| Â | Â | Follow-up | |||
|---|---|---|---|---|---|
Study | Methodological quality | 6 weeks | 3 months | 6 months | 1 year |
Physician-reported | Â | Â | Â | Â | Â |
Ogonda et al. [34] * | High | 0.08 (-0.18, 0.35) | NR | NR | NR |
Dorr et al. [26] * | Medium | NE (NS) | NR | NE (NS) | NR |
Ciminiello et al. [24] * | Medium | 0.26 (-0.10, 0.62) | NR | NR | NR |
Dutka et al. [27] * | Medium | NE (S) a | NE (NS) | NE (NS) | NR |
Speranza et al. [36] * | Medium | NR | NE (NS) | NE (NS) | NR |
Hart et al. [28]†| Medium | NR | NE (S) a | NE (NS) | NE (NS) |
Mazoochian et al. [37] * | Medium | NE (NS) | NE (S) a | NR | NR |
DiGioia et al. [17] * | Medium | NR | NE (S) a | NE (S) a | NE (NS) a |
De Beer et al. [25] * | Medium | 0.40 (-0.11, 0.91) | NR | NR | NR |
Nakamura et al. [33]†| Medium | NR | NR | NE (NS) | NR |
Patient-reported | Â | Â | Â | Â | Â |
Ogonda et al. [34]‡ | High | 0.03 (-0.23, 0.30) | NR | NR | NR |
Ogonda et al. [34]§ | High | 0.13 (-0.13, 0.40) | NR | NR | NR |
Ogonda et al. [34] ** | High | 0.01 (-0.26, 0.27) | NR | NR | NR |
Khan et al. [29]‡ | Medium | NR | NE (S) a | NR | NE (S) a |
Khan et al. [29]††| Medium | NR | NE (NS) | NR | NR |
Mazoochian et al. [37]‡ | Medium | NE (S) a | NE (S) a | NR | NR |
Speranza et al. [36]‡ | Medium | NR | NE (NS) | NE (NS) | NR |
De Beer et al. [25]§ | Medium | 0.24 (-0.27, 0.74) | NR | NR | NR |
Gait analysis b | Â | Â | Â | Â | Â |
Lawlor et al. [31] | High | -0.10 (-0.37, 0.16) | NR | NR | NR |
Ogonda et al. [34] | High | 0.19 (-0.07, 0.46) | NR | NR | NR |
Bennet et al. [22] | Medium | NE (NS) | NR | NR | NR |
Dorr et al. [26] | Medium | NE (NS) | NE (NS) | NR | NR |